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ABSTRACT
Background. For esophageal cancer, the number of
retrieved lymph nodes (LNs) is often used as a quality
indicator. The aim of this study is to analyze the number of
retrieved LNs in The Netherlands, assess factors associated
with LN yield, and explore the association with short-term
outcomes. This is a population-based study on lymph node
retrieval in patients with esophageal cancer, presenting
results from the Dutch Upper Gastrointestinal Cancer Audit.
Study Design. For this retrospective national cohort study,
patients with esophageal carcinoma who underwent
esophagectomy between 2011 and 2016 were included.
The primary outcome was the number of retrieved LNs.
Univariable and multivariable regression analyses were
used to test for association with C 15 LNs.
Patients and Results. 3970 patients were included.
Between 2011 and 2016, the median number of LNs
increased from 15 to 20. Factors independently associated
with C 15 LNs were: 0–10 kg preoperative weight loss
(versus: unknown weight loss, odds ratio [95% confidence
interval]: 0.71 [0.57–0.88]), Charlson score 0 (versus:
Charlson score 2: 0.76 [0.63–0.92]), cN2 category (refer-
ence: cN0, 1.32 [1.05–1.65]), no neoadjuvant therapy and
neoadjuvant chemotherapy (reference: neoadjuvant
chemoradiotherapy, 1.73 [1.29–2.32] and 2.15
[1.54–3.01]), minimally invasive transthoracic (reference:
open transthoracic, 1.46 [1.15–1.85]), open transthoracic
(versus open and minimally invasive transhiatal, 0.29
[0.23–0.36] and 0.43 [0.32–0.59]), hospital volume of
26–50 or [ 50 resections/year (reference: 0–25, 1.94
[1.55–2.42] and 3.01 [2.36–3.83]), and year of surgery
[reference: 2011, odds ratios (ORs) 1.48, 1.53, 2.28, 2.44,
2.54]. There was no association of C 15 LNs with short-
term outcomes.
Conclusions. The number of LNs retrieved increased
between 2011 and 2016. Weight loss, Charlson score, cN
category, neoadjuvant therapy, surgical approach, year of
resection, and hospital volume were all associated with
increased LN yield. Retrieval of C 15 LNs was not asso-
ciated with increased postoperative morbidity/mortality.
Since the relationship between the number of retrieved
LNs and survival was shown, the number of retrieved
lymph nodes (LNs) has often been used as a quality indi-
cator for esophageal cancer surgery.1–5
In 2013, the total number of retrieved LNs was intro-
duced as one of the quality indicators in the Dutch Upper
Gastrointestinal Cancer Audit (DUCA).6 This nationwide
audit aims to provide insight into the quality of delivered
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care by reporting reliable and benchmarked information on
process and outcome parameters, defined as ‘‘quality
indicators.’’ The 7th edition of the Union for International
Cancer Control (UICC)/American Joint Committee on
Cancer (AJCC) classification recommended removal of at
least 15 LNs for reliable staging of gastric cancer.7 Hence,
the number of 15 nodes was introduced as a quality indi-
cator for esophageal cancer.
It is unclear whether introduction of this indicator
resulted in higher LN yield. Furthermore, it is unknown
which factors are associated with the number of LNs
retrieved and whether higher LN yield is associated with
higher postoperative morbidity or mortality.
The aim of this study is to evaluate trends in the number of
retrieved lymph nodes and the proportion of patients with
C 15 LNs in the resection specimen. The second aim is to
identify patient, tumor, and treatment factors associated with
the number of retrieved LNs, LN yield, and thirdly, to
evaluate whether higher LN yield is associated with
increased morbidity and/or 30-day/in-hospital mortality.
METHODS
Study Design
Data were retrieved from the DUCA. This surgical audit was
initiated in 2011 and is part of the Dutch Institute for Clinical
Auditing (DICA). All patients with esophageal or gastric cancer
with intent of resection should be registered. Results on quality
indicators are reported to the participating hospitals. Each year,
external quality indicators are made transparent to the public,
policy-makers, insurance companies, and patient federations.
Validation of completeness and accuracy of data registration is
performed.6 For this study, patient, tumor, and treatment
characteristics, pathological information, and postoperative
outcome (until 30 days after operation) were retrieved from the
DUCA. Because patient and hospital identity are anonymous in
the database, it was not possible to retrieve missing data or
additional variables in retrospect.
Patient Selection
All patients undergoing surgery for esophageal cancer
with curative intention between 2011 and 2016 were
included. Patients with unknown date of birth, unknown
survival status at 30 days after surgery or discharge (in
case of hospital stay[ 30 days), or with unknown number
of retrieved LNs were excluded.
Since 2010, nCRT followed by surgery has been the
standard treatment according to the Dutch guideline for
esophageal carcinoma (with the exception of T1N0
tumors).8
Outcomes
Primary outcomes were the number of retrieved LNs (as
documented by the pathologist based on examination of the
resection specimen) and the percentage of patients with
C 15 LNs retrieved (as defined by the number of patients
with at least 15 retrieved LNs relative to the total number
of patients who underwent resection).
No informed consent or ethical approval was required
under Dutch law.
Statistical Analysis
To compare patient, tumor, and treatment characteristics
and surgical outcomes between the groups with C 15 LNs
and with \ 15 LNs, the v2 test was used. To identify
associated factors, univariable and multivariable logistic
regression analyses were performed. Factors with P value
\ 0.10 on univariable analyses or clinically relevant were
included in multivariable analyses. For all analyses, sta-
tistical significance was defined as P\ 0.05. All analyses
were performed using SPSS version 24 (IBM, Armonk,
NY, USA) and R (R Studio, version 0.99.903, Inc., with
package ‘‘ggplot2’’).
Possible factors associated with LN yield were selected
by the scientific committee of the DUCA based on litera-
ture. Consensus was reached for the factors age,
preoperative weight loss, Body Mass Index (BMI), tumor
location, American Society of Anesthesiologists (ASA)
score, Charlson comorbidity score,9 clinical T-, N-, and
M-category of the tumor, neoadjuvant chemo(radio)ther-
apy, surgical approach (minimally invasive or open, and
transhiatal or transthoracic), annual hospital volume, and
year of surgery. For evaluation of minimally invasive
approaches, stratified multivariable analysis for transhiatal
and transthoracic was used. To assess the relationship
between C 15 LNs and surgical outcomes, yield of C 15
LNs was analyzed in relation to nonradicality of the
resection (resection margins not free of tumor cells),
intraoperative complications, postoperative complications,
and 30-day and/or in-hospital mortality. A severe compli-
cation was defined as a complication leading to hospital
stay[ 21 days, reintervention or death.
RESULTS
A total of 4076 patients who underwent esophagectomy
for esophageal carcinoma were registered in the DUCA
between 2011 and 2016. Some patients were excluded
because date of birth was missing (n = 12), survival status
after 30 days/at discharge was missing (n = 80), or the
number of LNs was not documented (n = 14). Hence, a
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total of 3970 patients was included in the study analyses
(Supplementary Fig. S1).
Number of Retrieved LNs
The median number of retrieved LNs increased from 15
[interquartile range (IQR) 10–21] in 2011 to 20 (IQR
16–27) in 2016 (Fig. 1). Overall, the percentage of patients
with C 15 LNs was 69%. Among patients with C 15 LNs,
the median number of retrieved LNs was 22 (IQR 18–28),
and in the group of patients with\ 15 LNs, this number
was 11 (IQR 8–13). The percentage of patients with C 15
retrieved LNs increased from 51% in 2011 to 81% in 2016.
In 2011, the percentage of patients with C 15 retrieved
LNs ranged between 0 and 77% among hospitals. In 2016,
this variation between hospitals decreased (Fig. 2).
Factors Associated with C 15 LNs
Patient, tumor, treatment, and hospital characteristics
are presented in Table 1. Factors associated with\ 15 LNs
were Charlson score 2 (reference: Charlson score 0, 0.76
[0.63–0.92]) and unknown preoperative weight loss (ref-
erence: 0–10 kg weight loss, odds ratio [95% confidence
interval] 0.71 [0.57–0.88]) (Table 2).
Factors associated with C 15 LNs were clinical N2
category (reference: clinical N0, 1.32 [1.05–1.65]), no
neoadjuvant therapy and neoadjuvant chemotherapy (ref-
erence neoadjuvant chemoradiotherapy, 1.73 [1.29–2.32]
and 2.15 [1.54–3.01]), resection in a hospital with 26–50 or
[ 50 resections per year (reference: 0–25 resections, 1.94
[1.55–2.42] and 3.01 [2.36–3.83]), and resection between
2012 and 2016 (reference: 2011, ORs 1.48 [1.13–1.94],
1.53 [1.17–2.00], 2.28 [1.73–3.00], 2.44 [1.85–3.21], and
2.54 [1.91–3.39] for the years 2012 through 2016).
Transthoracic (open or minimally invasive) approach
was associated with a higher percentage of patients with
C 15 LNs (versus open or minimally invasive transhiatal
approach, 0.29 [0.23–0.36] and 0.43 [0.32–0.59]).
Stratified multivariable analysis for transthoracic resec-
tions showed a statistically significant association of
minimally invasive approach with yield C 15 LNs (refer-
ence: open transthoracic approach, 1.46 [1.15–1.85]).
There was no such association for minimally invasive
transhiatal resection with C 15 LNs (reference: open
transhiatal resection, 1.31 [0.97–1.75]).
LN Yield in Relation to Short-term Surgical Outcomes
Table 3 presents the association of C 15 LNs with short-
term outcomes (with \ 15 LNs as reference group). LN
yield C 15 was independently associated with fewer
intraoperative complications (4.5% vs. 6.8%, OR 0.69
[0.50–0.95]). Postoperative complications were more fre-
quent in patients with C15 LNs than in patients with\ 15
LN, but multivariable analysis showed no statistically
significant association (Table 3).
DISCUSSION
Between 2011 and 2016, the percentage of patients with
at least 15 retrieved LNs in esophageal cancer surgery
increased on a national level as well as for the individual
hospitals.
Our results show an association of C 15 LNs with
higher clinical N-category. It may be possible that, in
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patients with clinically suspicious positive lymph nodes,
the surgeon is particularly focused on more complete LN
dissection. Also, tumor-positive LNs are often increased in
size and therefore easier to identify during the operation
and during pathological examination of the resection
specimen. This could result in a higher number of retrieved
LNs. Another explanation is that the immune response
against the tumor influences the number of retrieved LNs.
It has been suggested that larger tumors may cause a more
intense immune response, leading to hyperplasia of local
LNs, which could increase LN detectability.10 However,
this hypothesis is not proven yet.
It is well known that the type of surgical approach in
esophageal resection influences the number of retrieved
LNs; i.e., transthoracic as compared with transhiatal
approach is associated with a higher number of LNs
retrieved, as also seen in the current study.11,12 Regarding
the impact of a minimally invasive approach on LN yield,
conflicting results have been published. A systematic
review showed no differences between open and minimally
invasive surgery, while another meta-analysis showed
significantly higher LN retrieval in minimally invasive
surgery (16 vs. 10, P = 0.03).13,14 In the present study,
higher LN retrieval was seen especially in minimally
invasive transthoracic procedures, which is in accordance
with a recent propensity-score-matched analysis also using
data from the DUCA [20 (2–59) vs. 18 (0–53) LNs;
P\ 0.001].15 It is possible that minimally invasive surgery
offers benefits in terms of magnification and visibility of
surgical structures and planes, which may translate into
higher LN yield.
Busweiler et al. recently showed that, in patients
undergoing gastrectomy, the percentage of patients with
C 15 retrieved LNs was higher in hospitals with higher
composite hospital volume (gastrectomies, esophagec-
tomies, and pancreatectomies).16 In our study, a similar
association was noticed for esophageal cancer surgery. It is
suggested that hospitals performing this type of surgery
may benefit from the in-hospital experience.16 More
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TABLE 1 Basic characteristics of study population, including score of % of patients with C 15 lymph nodes for each subgroup
Patient characteristic Total n (%) Results on the quality indicator
\ 15 LNs C 15 LNs P value*
Total 3970 31% 69%
Gender 0.83
Male 3077 (78%) 31% 69%
Female 892 (23%) 31% 69%
Unknown 1 (0.0%) 0% 100%
Age (in years) 0.002
0–64 1787 (45%) 29% 71%
65–74 1650 (42%) 31% 69%
75 ? 533 (13%) 37% 63%
Preoperative weight loss (kg) \ 0.001
0–5 2154 (54%) 29% 71%
6–10 835 (21%) 31% 69%
10 ? 443 (11%) 33% 67%
Unknown 538 (14%) 38% 62%
Body Mass Index (kg/m2) 0.48
\ 20 257 (6.5%) 34% 66%
20–24 1512 (38%) 31% 70%
25–29 1522 (38%) 30% 70%
30 ? 635 (16%) 33% 67%
Unknown 44 (1.1%) 41% 59%
Tumor location in
esophagus
\ 0.001
Cervical 4 (0.1%) 50% 50%
Proximal 40 (1.0%) 15% 85%
Mid 486 (12%) 25% 76%
Distal 2504 (63%) 31% 69%
Gastroesophageal junction 936 (24%) 36% 65%
ASA score 0.08
I–II 3070 (77%) 30% 70%
III ? 880 (22%) 33% 67%
Unknown 20 (0.5%) 50% 50%
Charlson score 0.002
0 1939 (49%) 29% 71%
1 1012 (26%) 31% 69%
2 ? 1019 (26%) 35% 65%
Clinical T-category 0.63
cT0–1 209 (5.3%) 29% 71%
cT2 736 (19%) 33% 67%
cT3 2731 (69%) 31% 69%
cT4 135 (3.4%) 29% 71%
Unknown 159 (4.0%) 31% 69%
Clinical N-category 0.001
cN0 1407 (35%) 33% 67%
cN1 1591 (40%) 31% 69%
cN2 716 (18%) 26% 74%
cN3 100 (2.5%) 25% 75%
cN? (count unknown) 42 (1.1%) 29% 71%
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intensive cooperation of a multidisciplinary team could be
important for quality improvement initiatives.
This study showed an increase in the number of LNs
every year. It is expected that, since the introduction of
quality indicators in the DUCA, quality improvement ini-
tiatives in all hospitals have been initiated, because the
results of these indicators are transparent for all individual
hospitals each year. The national healthcare inspectorate,
health insurance authorities, and different federations use
the outcomes of this indicator to assess the quality of upper
gastrointestinal surgical care in hospitals in The Nether-
lands. The increased numbers of retrieved LNs over the
years could be the result of increased awareness of the
importance of LN dissection by surgeons. On the other
hand, back table dissection of the specimen and more
extensive pathological assessment as a result of dedication
of the pathologist could be major explanations as well. All
these explanations have likely contributed to improving
quality of care. The role of the pathologists in identifying
nodes in the resection specimen is very important, as the
TABLE 1 continued
Patient characteristic Total n (%) Results on the quality indicator
\ 15 LNs C 15 LNs P value*
Unknown 114 (2.9%) 45% 55%
Clinical M-category 0.85
cM0 3837 (97%) 31% 69%
cM1 34 (0.9%) 29% 71%
Unknown 99 (2.5%) 34% 66%
Neoadjuvant therapy 0.05
No 324 (8.2%) 28% 73%
Chemotherapy 253 (6.4%) 26% 74%
Chemoradiotherapy 3373 (85%) 32% 68%
Surgical approach \ 0.001
TTE thoracic part open 694 (18%) 27% 73%
TTE thoracic part MI 1984 (50%) 18% 82%
THE open 935 (24%) 56% 44%
THE MI 344 (8.7%) 45% 55%
Unknown 13 (0.3%) 69% 31%
Salvage resection 0.75
No 3870 (98%) 31% 69%
Yes 55 (1.4%) 29% 71%
Unknown 45 (1.1%) 29% 71%
Hospital volume (average
number of resections/year)
\ 0.001
0–25 522 (13%) 53% 47%
26–50 2194 (55%) 29% 71%
50 ? 1229 (31%) 24% 76%
Stopped before 2014 25 (0.6%) 76% 24%
Year of resection \ 0.001
2011 491 (12%) 50% 50%
2012 613 (15%) 39% 62%
2013 641 (16%) 37% 63%
2014 702 (18%) 26% 74%
2015 778 (20%) 24% 76%
2016 745 (19%) 20% 80%
ASA American Society of Anesthesiologists, TTE transthoracic esophagectomy, THE transhiatal esophagectomy, MI minimally invasive, LNs
lymph nodes
*Chi-squared analysis, in case of\ 5% ‘‘unknown,’’ this category was not included in the statistical analysis (exception: cN-category)
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TABLE 2 Multivariable logistic regression analysis for factors associated with C 15 LNs
Characteristic n Multivariable analysis
Total 3970 P value OR 95% CI
Age (years) 0.29
0–64 1756 ref
65–74 1615 0.67 0.96 0.82–1.14
75 ? 521 0.12 0.83 0.66–1.05
Preoparative weight loss (kg) 0.01
0–10 2938 ref
10.1–15 261 0.12 0.79 0.59–1.06
[15 174 0.19 0.78 0.54–1.13
Unknown 519 \ 0.001 0.71 0.57–0.88
Tumor location in esophagus 0.59
Cervical 4 0.41 0.40 0.05–3.46
Proximal 39 0.22 1.80 0.71–4.54
Mid 480 0.68 0.95 0.74–1.22
Distal 2451 ref
Gastroesophageal junction 918 0.59 1.05 0.87–1.27
ASA score 0.77
I–II 3020 ref
III? 872 1.03 0.85–1.24
Charlson score 0.02
0 1897 ref
1 998 0.68 0.96 0.80–1.16
2 ? 997 0.01 0.76 0.63–0.92
Clinical N-category 0.02
cN0 1383 ref
cN1 1553 0.37 1.08 0.91–1.29
cN2 707 0.02 1.32 1.05–1.65
cN3 99 0.15 1.47 0.87–2.48
cN? (count unknown) 41 0.30 1.50 0.70–3.19
Unknown 109 0.07 0.67 0.43–1.03
Neoadjuvant therapy \ 0.001
No 322 \ 0.001 1.73 1.29–2.32
Chemotherapy 249 \ 0.001 2.15 1.54–3.01
Chemoradiotherapy 3321 ref
Surgical approach \ 0.001
TTE thoracic part open (incl. MI abdomen) 686 ref
TTE thoracic part MI 1968 0.004 1.38 1.11–1.73
THE open 912 \ 0.001 0.29 0.23–0.36
THE MI 326 \ 0.001 0.43 0.32–0.59
Hospital volume (average number of resections/year) \ 0.001
0–25 506 ref
26–50 2174 \ 0.001 1.94 1.55–2.42
[ 50 1212 \ 0.001 3.01 2.36–3.83
Year of resection \ 0.001
2011 462 ref
2012 599 0.01 1.48 1.13–1.94
2013 616 0.00 1.53 1.17–2.00
2014 699 \ 0.001 2.28 1.73–3.00
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time spent doing this makes a great difference.17 In this
study, the role of the pathologist could not be studied, but
dedicated pathologists or technicians are associated with
increased number of nodes detected.18,19
More extensive LN dissection may lead to better
locoregional tumor control. However, the importance of
LN dissection for locoregional tumor control has been
debated since the introduction of neoadjuvant chemora-
diotherapy. It is known that neoadjuvant
chemoradiotherapy leads to tumor and lymph node down-
staging, resulting in more resections with negative margins
and lymph nodes.20 The study of Talsma et al. showed that
the number of retrieved LNs had a prognostic impact for
patients who underwent surgery without neoadjuvant
chemoradiotherapy, but not in the group of patients who
underwent neoadjuvant chemoradiotherapy.21 For patients
treated with neoadjuvant chemotherapy, Markar et al. also
showed lower recurrence rate and improved survival for
patients with higher lymph node yield. Similarly, effects of
higher lymph node yield on survival or recurrence were not
observed in patients treated with neoadjuvant chemora-
diotherapy.22 In the current study, we observed an inverse
correlation between neoadjuvant chemoradiotherapy and
retrieved LNs, which has been reported before.11,21,23,24 An
explanation for this phenomenon could be that use of
neoadjuvant chemoradiotherapy leads to less priority for
extended LN dissection by Dutch surgeons, or that
neoadjuvant treatment, especially neoadjuvant
TABLE 2 continued
Characteristic n Multivariable analysis
Total 3970 P value OR 95% CI
2015 774 \ 0.001 2.44 1.85–3.21
2016 742 \ 0.001 2.54 1.91–3.39
ASA American Society of Anesthesiologists, TTE transthoracic esophagectomy, THE transhiatal esophagectomy, MI minimally invasive, OR
odds ratio, CI confidence interval
TABLE 3 Surgical outcomes associated with C 15 LNs
Outcomes \ 15 LNs %
(n)
C15 LNs %
(n)
Univariable analysis Multivariable analysis
(with outcomes as dependent variable)
OR [95% CI] C 15
LNs
P value OR [95% CI] C 15
LNs
P value
Positive resection margins 5.6% (68) 4.9% (132) 1.16 [0.86–1.57] 0.33
Intraoperative complications 6.8% (83) 4.5% (122) 0.64 [0.48–0.86] 0.003 0.69 [0.50–0.95]^ 0.02
Bleeding (with transfusion) 22% (18) 16% (20)
Intestinal injury 9.6% (8) 5.8% (7)
Spleen injury 13% (11) 17% (20)
Other 55% (46) 61% (75)
Postoperative complications 57% (702) 61% (1667) 1.17 [1.02–1.34] 0.02 1.01 [0.93–1.27]* 0.28
Pulmonary 29% (356) 32% (879)
Cardiac 12% (150) 15% (401)
Anastomotic leakage/local necrosis
conduit
20% (241) 18% (503)
Chylous leakage 5% (58) 8% (240)
Severe postoperative complications 28% (339) 31% (847) 1.18 [1.01–1.37] 0.03 1.00 [0.85–1.19]* 0.98
30-day/in-hospital mortality 4.2% (52) 3.5% (95) 0.82 [0.58–1.15] 0.24
ASA American Surgical Association, LNs lymph nodes, OR odds ratio, CI confidence interval
^Adjusted for: Body Mass Index, ASA score, surgical approach, year of resection
*Adjusted for: age, Body Mass Index, Charlson score, ASA score, histological type, tumor location, surgical approach, hospital volume
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chemoradiotherapy, may induce regression of LNs, as
reported before.10 So, despite radical resection, fewer LNs
are retrieved or detected by the pathologist. Unfortunately,
the DUCA registry has no long-term follow-up. Hence, it
cannot be concluded from the results of this study whether
the number of retrieved LNs is a valid indicator for the
quality of locoregional tumor treatment. Nonetheless, this
indicator may be meaningful as an indicator for overall
quality of esophageal cancer care. Higher number of
retrieved LNs may lead to improved tumor staging, and
complete pathological staging is essential to predict the
prognosis of patients. Furthermore, in patients treated with
neoadjuvant chemoradiotherapy, signs of tumor regression
in LNs (instead of positive LNs) are a better predictor of
prognosis than clinical N-category, which is not always
easy to assess preoperatively.
CONCLUSIONS
Pro and contra arguments can be provided for use of a
minimal number of retrieved LNs as a quality indicator in
clinical auditing. An argument for the use of this indicator
in clinical auditing is that it reveals relevant variation in
outcomes of hospitals, which seems to distinguish between
them. Another advantage could be that this indicator may
lead to better quality of esophageal cancer because of
quality improvement initiatives. However, the validity of
this indicator as a direct measure of the quality of LN
dissection is questionable, and the effect of more retrieved
LNs on tumor control is debatable since the introduction of
neoadjuvant chemoradiotherapy. Nevertheless, higher
lymph node retrieval does not seem to lead to higher
morbidity or mortality, so the number of retrieved LNs can
safely be used as an indicator for quality of care.
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